Vitiligo Review: etiopathogenesis, diagnosis and treatment
DOI:
https://doi.org/10.12775/QS.2025.37.57367Keywords
vitiligo, phototherapy, autoimmune diseases, melanocytes, corticosteroidsAbstract
Introduction and purpose:This review is intended for healthcare professionals, including dermatologists, primary care physicians, and researchers, who seek a comprehensive understanding of vitiligo. It is also relevant for patients and their families to better understand the condition. The review is indicated for those dealing with cases of vitiligo that are difficult to diagnose or manage, those with widespread or refractory vitiligo, and individuals interested in the latest advancements in treatment. The purpose of this review is to provide a detailed analysis of vitiligo’s etiopathogenesis, the current diagnostic methods, and the most effective treatment options. By exploring the genetic, autoimmune, and environmental factors involved in vitiligo, the review aims to enhance the understanding of the disease's origin and progression. Additionally, it seeks to offer evidence-based insights into the most up-to-date diagnostic tools and therapeutic approaches, ultimately improving patient care and guiding future research directions.
State of knowledge:
Vitiligo is an autoimmune disorder characterized by the loss of melanocytes, leading to depigmented skin patches. Its exact cause remains unclear, but genetic and environmental factors, such as stress and skin trauma, are thought to contribute. Diagnosis is primarily clinical, with dermoscopy and biopsy used in uncertain cases. While treatments like topical corticosteroids, phototherapy, and JAK inhibitors are effective for some, no cure exists, and responses vary widely. Surgical options like melanocyte transplantation can help with localized cases. Ongoing research aims to better understand the disease mechanisms and improve treatment outcomes.
References
Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571-592. doi: 10.1159/000506103. Epub 2020 Mar 10. PMID: 32155629.
Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020 Apr 26;38:621-648. doi: 10.1146/annurev-immunol-100919-023531. Epub 2020 Feb 4. PMID: 32017656.
Bergqvist C, Ezzedine K. Vitiligo: A focus on pathogenesis and its therapeutic implications. J Dermatol. 2021 Mar;48(3):252-270. doi: 10.1111/1346-8138.15743. Epub 2021 Jan 6. PMID: 33404102.
Spritz RA, Santorico SA. The Genetic Basis of Vitiligo. J Invest Dermatol. 2021 Feb;141(2):265-273. doi: 10.1016/j.jid.2020.06.004. Epub 2020 Aug 8. PMID: 32778407.
van Geel N, Speeckaert R. Segmental Vitiligo. Dermatol Clin. 2017 Apr;35(2):145-150. doi: 10.1016/j.det.2016.11.005. PMID: 28317524.
van Geel N, Speeckaert R, Taïeb A, Ezzedine K, Lim HW, Pandya AG, Passeron T, Wolkerstorfer A, Abdallah M, Alomar A, Bae JM, Bekkenk M, Benzekri L, Böhm M, Eleftheriadou V, Esmat S, Ghia D, Goh BK, Grimes P, Gupta S, Hamzavi IH, Harris JE, Oh SH, Huggins R, Katayama I, Lan E, Lee AY, Leone G, Le Poole C, Lui H, Maquignon N, Meurant JM, Monteiro P, Oiso N, Parsad D, Pliszewski G, Raboobee N, Rodrigues M, Rosmarin D, Suzuki T, Tanemura A, Thng S, Xiang F, Zhou Y, Picardo M, Seneschal J. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2173-2184. doi: 10.1111/jdv.19451. Epub 2023 Sep 25. PMID: 37746876.
Seneschal J, Harris JE, Le Poole IC, Passeron T, Speeckaert R, Boniface K. Editorial: Immunology of Vitiligo. Front Immunol. 2021 Jun 24;12:711080. doi: 10.3389/fimmu.2021.711080. PMID: 34249018; PMCID: PMC8264751.
van Geel N, Speeckaert M, Brochez L, Lambert J, Speeckaert R. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014 Jun;28(6):741-6. doi: 10.1111/jdv.12169. Epub 2013 Apr 17. PMID: 23590677.
Gatti RA. Aetiology of vitiligo. Lancet. 1972 Jan 8;1(7741):91. doi: 10.1016/s0140-6736(72)90083-9. PMID: 4108962.
Grimes PE. Vitiligo. An overview of therapeutic approaches. Dermatol Clin. 1993 Apr;11(2):325-38. PMID: 8477546.
Shin JU, Roh MR, Lee JH. Vitiligo following intense pulsed light treatment. J Dermatol. 2010 Jul;37(7):674-6. doi: 10.1111/j.1346-8138.2010.00834.x. PMID: 20629836.
Plott RT, Wagner RF. Modern treatment approaches to vitiligo. Cutis. 1990 May;45(5):311-6. PMID: 2192829.
Korsunskaya IM, Suvorova KN, Dvoryankova EV. Modern aspects of vitiligo pathogenesis. Dokl Biol Sci. 2003 Jan-Feb;388:38-40. doi: 10.1023/a:1022443809606. PMID: 12705126.
Rmadi N, Kotti N, Bahloul E, Dhouib F, Sellami I, Sellami K, Jmal Hammami K, Masmoudi ML, Turki H, Hajjaji M. Role of chemical exposure in the incidence of vitiligo: a case-control study in Tunisia. Libyan J Med. 2023 Dec;18(1):2132628. doi: 10.1080/19932820.2022.2132628. PMID: 36433836; PMCID: PMC9707374.
Mandel AS, Haberman HF, Pawlowski D, Goldstein E. Non PUVA nonsurgical therapies for vitiligo. Clin Dermatol. 1997 Nov-Dec;15(6):907-19. doi: 10.1016/s0738-081x(97)00132-6. PMID: 9404694.
Sehgal VN, Srivastava G. Vitiligo: auto-immunity and immune responses. Int J Dermatol. 2006 May;45(5):583-90. doi: 10.1111/j.1365-4632.2005.02651.x. PMID: 16700798.
Cormane RH, Westerhof W, Siddiqui AH. Vitiligo [Vitiligo]. Ned Tijdschr Geneeskd. 1984 Sep 29;128(39):1855-9. Dutch. PMID: 6493378.
What you need to know about .... vitiligo. Nurs Times. 2003 Dec 9-15;99(49):27. PMID: 14705342.
Kumar Jha A, Sonthalia S, Lallas A, Chaudhary RKP. Dermoscopy in vitiligo: diagnosis and beyond. Int J Dermatol. 2018 Jan;57(1):50-54. doi: 10.1111/ijd.13795. Epub 2017 Oct 26. PMID: 29076154.
Koga M. Vitiligo: a new classification and therapy. Br J Dermatol. 1977 Sep;97(3):255-61. doi: 10.1111/j.1365-2133.1977.tb15180.x. PMID: 921895.
Mason SH, Cohen PR. Vitiligo. J Gt Houst Dent Soc. 1998 Feb;69(7):12-3. PMID: 9571875.
Kenney JA Jr. Vitiligo. Dermatol Clin. 1988 Jul;6(3):425-34. PMID: 3168334.
Menke HE, van Everdingen JJ. Richtlijn 'vitiligo' [The practice guideline 'vitiligo']. Ned Tijdschr Geneeskd. 2006 Sep 9;150(36):1976-81. Dutch. PMID: 17002186.
Wang X, McCoy J, Lotti T, Goren A. Topical cream delivers NB-UVB from sunlight for the treatment of vitiligo. Expert Opin Pharmacother. 2014 Dec;15(18):2623-7. doi: 10.1517/14656566.2014.978287. Epub 2014 Nov 3. PMID: 25363734.
Nordlund JJ. The epidemiology and genetics of vitiligo. Clin Dermatol. 1997 Nov-Dec;15(6):875-8. doi: 10.1016/s0738-081x(97)00128-4. PMID: 9404690.
Chan MF, Chua TL. The effectiveness of therapeutic interventions on quality of life for vitiligo patients: a systematic review. Int J Nurs Pract. 2012 Aug;18(4):396-405. doi: 10.1111/j.1440-172X.2012.02047.x. PMID: 22845640.
Hartmann A. Vitiligo. Diagnose, Differenzialdiagnose und aktuelle Therapieempfehlungen [Vitiligo. Diagnosis, differential diagnosis, and current patient management]. Hautarzt. 2009 Jun;60(6):505-14; quiz 515. German. doi: 10.1007/s00105-009-1770-9. PMID: 19444398.
Bacigalupi RM, Postolova A, Davis RS. Evidence-based, non-surgical treatments for vitiligo: a review. Am J Clin Dermatol. 2012 Aug 1;13(4):217-37. doi: 10.2165/11630540-000000000-00000. PMID: 22423621.
Mason CP, Gawkrodger DJ. Vitiligo presentation in adults. Clin Exp Dermatol. 2005 Jul;30(4):344-5. doi: 10.1111/j.1365-2230.2005.01779.x. PMID: 15953063.
Schild M, Meurer M. Vitiligo : Klinik und Pathogenese [Vitiligo: Clinical presentation and pathogenesis]. Hautarzt. 2016 Feb;67(2):173-86; quiz 187-9. German. doi: 10.1007/s00105-015-3751-5. PMID: 26781864.
Roohaninasab M, Mansouri P, Seirafianpour F, Naeini AJ, Goodarzi A. Therapeutic options and hot topics in vitiligo with special focus on pediatrics' vitiligo: A comprehensive review study. Dermatol Ther. 2021 Jan;34(1):e14550. doi: 10.1111/dth.14550. Epub 2020 Dec 7. PMID: 33200859.
Simons RE, Zevy DL, Jafferany M. Psychodermatology of vitiligo: Psychological impact and consequences. Dermatol Ther. 2020 May;33(3):e13418. doi: 10.1111/dth.13418. Epub 2020 May 4. PMID: 32297399.
Ribeiro RPS, Lacerda KAP, Guillo LA. Analysis of Serum Immunoglobulin G (IgG) Levels against Toxoplasma Gondii, Herpes Simplex Virus Types 1 and 2, Cytomegalovirus and Hepatitis C Virus in Vitiligo. Indian J Dermatol. 2023 Sep-Oct;68(5):588. doi: 10.4103/ijd.ijd_950_22. PMID: 38099098; PMCID: PMC10718258.
Yamamoto A, Yang L, Kuroda Y, Guo J, Teng L, Tsuruta D, Katayama I. Local Epidermal Endocrine Estrogen Protects Human Melanocytes against Oxidative Stress, a Novel Insight into Vitiligo Pathology. Int J Mol Sci. 2020 Dec 29;22(1):269. doi: 10.3390/ijms22010269. PMID: 33383933; PMCID: PMC7794688.
Savant SS. Surgical therapy of vitiligo: current status. Indian J Dermatol Venereol Leprol. 2005 Sep-Oct;71(5):307-10. doi: 10.4103/0378-6323.16778. PMID: 16394452.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aleksandra Witek, Jakub Parys, Agnieszka Mikosińska, Martyna Kaźmierczak, Maciej Mossakowski, Patrycja Kałuziak, Marta Jajczak, Mateusz Litwin, Stanisław Jesionek, RAfał Bieś
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 8
Number of citations: 0